Briefs: Zydus Lifesciences and Divi's Laboratories

Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets

New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant

Lupin and Huons Sign agreement for commercialization of cyclosporine ophthalmic nanoemulsion in Mexico

Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome

dsm-firmenich to sell MEG-3 fish oil business to KD Pharma Group

dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business

Budget 2024-25: Industry expects push for reforms, R&D and fiscal incentives

Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23

Zydus signs patent licensing agreement with Takeda for 'VaultA’ in India

The pooled prevalence of GERD in the Indian population is 15.6 %

Dr. Reddy's signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan

Lupin divests US commercial women's health specialty business to Evofem

Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones

Merck starts commercial production of first GMP-compliant manufacturing line for cell culture media in China

€ 6.6 million investment at Nantong site expands production capabilities for cell culture media

Merck completes acquisition of EyeBio

Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret